The budgets of operations and statistical centers of adult clinical trials groups were cut by about $20.4 million, group chairs say.
The cuts make it difficult for the groups to continue to support ongoing trials and raise questions about the prospects for starting a new generation of trials.
NCI officials say that, overall, the budget for the groups is staying flat, in part because some of the money is being channeled into 30 sites that received the Lead Academic Participating Site designation.
LAPS, which are run by cancer centers, will be allowed to charge more for putting patients on studies.
So where are the cuts?
|No Justification Provided|
AAUP Demands Reinstatement of Faculty Denied Tenure Renewal at MD Anderson
The American Association of University Professors sent a letter to Ronald DePinho, president of MD Anderson Cancer Center, urging the reinstatement of two faculty members who were denied tenure renewal without stated reasons.
The letter is a part of AAUP’s response to a request for an investigation, which was triggered by the administration’s refusal to provide justification for denying tenure renewals to faculty who received unanimous votes for renewal from the Faculty Senate Promotions & Tenure Committee.
|Report: Rising Treatment Costs Due to 340B Discounts|
The 340B drug discount program is causing a rise in the costs of treating cancer patients, according to a new report.
Published by the IMS Institute for Healthcare Informatics, the report, “Innovations in Cancer Care and Implications for Health Systems,” showed that marketplace behaviors, triggered by a lack of eligibility integrity, are a major reason for increasing costs of cancer care, said the Alliance for Integrity and Reform of 340B in a statement.
|TGen and George Mason Form Precision Medicine Alliance|
The Translational Genomics Research Institute and George Mason University announced a strategic research alliance May 6.
Called the TGen-George Mason Molecular Medicine Alliance, the effort is designed to recommend medications and treatments to clinicians based on each patient’s molecular profile.
Oncology Nursing Society names board of directors
American College of Radiology names new officers
Bristol-Myers Squibb and Celldex Therapeutics Inc. enter agreement
Moffitt Cancer Center collaborates with Vermillion Inc.
Children’s Oncology Drug Alliance helps form international collaborative